SCHEMBL35212261

SCHEMBL35212261

OCCc1cnn(C2CCCCO2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.38
FGFR1 P11362 2/20 0.38
FGFR2 P21802 1/20 0.38
FGFR4 P22455 1/20 0.38
FGFR3 P22607 1/20 0.38
KDR P35968 1/20 0.38
KDM5B Q9UGL1 1/20 0.37
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
CYP4F2 P78329 4/20 0.34
CYP4A11 Q02928 4/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
SYK P43405 1/20 0.33
AURKB Q96GD4 1/20 0.33
MCL1 Q07820 1/20 0.33
SCD O00767 1/20 0.31
ACHE P22303 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL878011 0.88 KDM5B (0.38) FLT3FGFR1FGFR2FGFR4FGFR3
SCHEMBL29525193 0.82 KDM5B (0.40) FLT3FGFR1FGFR2FGFR4FGFR3
SCHEMBL31510377 0.82 KDM5B (0.40) FLT3FGFR1FGFR2FGFR4FGFR3
SCHEMBL13035401 0.82 GABRA1 (0.39) FLT3FGFR1FGFR2FGFR4FGFR3
SCHEMBL22774288 0.82 KDM5B (0.40) FLT3FGFR1FGFR2FGFR4FGFR3
SCHEMBL15760929 0.82 RXRA (0.38) FLT3FGFR1FGFR2FGFR4FGFR3
SCHEMBL31065978 0.80 KDM4C (0.46) FLT3FGFR1FGFR2FGFR4FGFR3
SCHEMBL15286385 0.79 KDM5B (0.39) FLT3FGFR1FGFR2FGFR4FGFR3
SCHEMBL31180433 0.79 KDM5B (0.36) FLT3FGFR1FGFR2FGFR4FGFR3
SCHEMBL23600914 0.78 MGLL (0.40) KDM5BRXRARXRBRXRGCYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124205-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS INC (US) 2026-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124205-A1 MODULATORS OF BETA CATENIN AND USES THEREOF CTNNB1, CTNNA1, CTNND1 FLT3 4789/4885FGFR1 3659/4885FGFR2 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.